Preview Newsletter

XARELTO Media Monitoring – Week of 04-01-16

Client Attorney Privileged/Attorney Work Product/At Request of Counsel

Plaintiff Attorney Press Releases

Patients File Class Action Xarelto Lawsuit in Canada
Mar 26, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on the Calgary Sun’s article concerning Canadian patients who have filed Xarelto lawsuits. The lead plaintiff in Canada’s class action suit alleges that she suffered uncontrollable bleeding after taking Xarelto in 2012. She claims that after doctors struggled to control the bleeding, she went into cardiac arrest.
Portola Enters Agreement With Xarelto Manufacturer Bayer Amid Lawsuit Increases
Mar 26, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on Portola Pharmaceuticals’ announcement concerning a clinical collaboration with Bayer. Portola announced that it has decided to enter a collaboration with the manufacturers of Xarelto to include its Factor Xa inhibitor rivaroxaban in a clinical development program in Japan. Portola is developing an FDA designated breakthrough therapy called andexanet alfa to reverse anticoagulation in patients taking Factor Xa inhibitors such as Xarelto.
Xarelto Lawsuit Plaintiffs Note New York Times Article Discussing Potentially Defective Testing Device
Mar 28, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on the publication of a New York Times article which discussed an investigation by the U.S. Food and Drug Administration (FDA) into whether a recalled device used during Xarelto clinical testing could have affected the trial results leading up to the drug’s FDA approval in 2011.
Xarelto Lawsuit Plaintiff Requests $4.35 Million In Lawsuit Claiming Dangerous Bleeding Episode
Mar 28, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on another lawsuit that has been filed against Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation), and multiple other defendants, regarding new-generation anticoagulant Xarelto. The plaintiff filing suit claims that the anticoagulant caused him to suffer from a sudden and uncontrollable bleeding episode.
Texas Plaintiffs File Xarelto Lawsuit Complaint Alleging Manufacturers Neglected To Warn Consumers Of Drugs Dangers
Mar 29, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on another lawsuit which has been filed against Xarelto manufacturers Bayer Healthcare and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson) in reference to the anticoagulant drug they produce, Xarelto. Xarelto is a new-generation blood-thinning drug which has been on the market for five year’s time. In those five years, it has become the topic of thousands of lawsuits from across the United States.
Xarelto Lawsuit Plaintiff Requests $4.35 Million In Lawsuit Claiming Dangerous Bleeding Episode
Mar 29, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on another lawsuit that has been filed against Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation), and multiple other defendants, regarding new-generation anticoagulant Xarelto. The plaintiff filing suit claims that the anticoagulant caused him to suffer from a sudden and uncontrollable bleeding episode.
An Overview Of FDA Warnings Leading Into Building Xarelto Lawsuit Numbers
Mar 29, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on the warnings issued by the FDA for the blood-thinning drug Xarelto since its approval in 2011. According to the FDA, Xarelto, manufactured by Johnson & Johnson and Bayer AG, has undergone several required warnings and changes to labeling and advertisements for the drug since it was approved.
Xarelto Lawsuit Numbers Continue To Increase As New Controversies Emerge Surrounding Drug
Mar 29, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on an article recently published on Health News Review by a guest blogger psychiatrist from the Washington, DC area. The article discusses what many different media outlets have been reporting recently: controversies surrounding critical clinical trials conducted on blood-thinning drug Xarelto, as well as data which may have been left out of a report to the New England Journal of Medicine.
Calgary Canada Class Action Xarelto Lawsuit Filed As Another Class Action Suit Is Likely Forming In Ontario
Mar 30, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on an article recently published in the Calgary Sun discussing the a class action lawsuit which was filed against Bayer Inc., one manufacturer of the new-generation, blood-thinning drug Xarelto in Calgary, Canada. According to the head plaintiff in this Canadian class action lawsuit, the drug caused her to suffer from an uncontrollable bleeding episode which allegedly almost led to cardiac arrest.
Xarelto Lawsuit Numbers Continue To Increase As New Controversies Emerge Surrounding Drug
Mar 30, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on an article recently published on Health News Review by a guest blogger psychiatrist from the Washington, DC area. The article discusses what many different media outlets have been reporting recently: controversies surrounding critical clinical trials conducted on blood-thinning drug Xarelto, as well as data which may have been left out of a report to the New England Journal of Medicine.
Woman Files Xarelto Lawsuit Alleging Life-Threatening Bleeding Incidents From Drug
Mar 30, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on a lawsuit that has been added to MDL No. 2592 in Eastern Louisiana in February. The plaintiff alleges that after taking Xarelto, manufactured by Bayer AG and Johnson & Johnson, from January 2014 to February 2014, she suffered serious bleeding incidents that she claims were a direct result of the drug. The suit contains 12 actions against the manufacturers including allegations that the companies failed to adequately warn patients about possible side effects and the fact that when the drug was released to the market there was no reversal agent. An antidote still has not been approved.
Xarelto Lawsuit Plaintiffs Take Note Of New Controversies Surrounding Anticoagulant Drug
Mar 29, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on new controversies surrounding blood-thinning drug Xarelto after,“...a document claimed that two major pharmaceutical companies may have misled a medical journal by leaving out some critical data on their drug,” according to a recent online article from Business Insider.
Xarelto Lawsuit Claims Drug Caused Hemorrhagic Pericardial Effusion
Mar 30, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on an Arizona lawsuit that alleges the blood-thinning drug, Xarelto, caused a woman to suffer a life-threatening hemorrhagic pericardial effusion, a medical condition in which blood fills the sac around the heart and gets in the way of normal heart contractions. The woman who filed case number 2:16-cv-01359 claimed that she took Xarelto for less than two weeks and that she was diagnosed in 2014 with hemorrhagic pericardial effusion, pericardial tamponade and pleural effusion. In addition to claims that Xarelto was the reason for this diagnosis, the case further claims that Bayer AG and Johnson & Johnson withheld information about the lack of antidote, when the drug was released to the market, to reverse the drug's blood-thinning effects.
NJ Resident Files Xarelto Lawsuit Claiming Drug Caused Nearly Fatal GI Bleeding Episode
Mar 30, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on another lawsuit which has been filed against Bayer AG and Janssen Pharmaceuticals in relation to the anticoagulant drug they manufacture, Xarelto. The complaint was filed under case number 2:15-cv-06264 in the U.S. District Court for the Eastern District of Louisiana on November 23rd, 2015. The plaintiff filing is a New Jersey resident who claims that these manufacturers have failed to sufficiently warn current and potential patients about certain health risks which are potentially linked to the new-generation blood thinner.
Xarelto Plaintiffs From Texas File Lawsuit Claiming Drugs Manufacturers Failed To Warn Consumers Of Concerning Side Effects
Mar 31, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on concerning details from a lawsuit filed against Xarelto manufacturers Bayer AG and Johnson & Johnson subsidiary Janssen Pharmaceuticals. Xarelto is a new-generation blood-thinning drug which first appeared on the market in 2011, providing blood thinner patients with new freedoms that traditional blood thinners had been unable to.
NJ Resident Files Xarelto Lawsuit Claiming Drug Caused Nearly Fatal GI Bleeding Episode
Apr 1, 2016 | Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on another lawsuit which has been filed against Bayer AG and Janssen Pharmaceuticals in relation to the anticoagulant drug they manufacture, Xarelto. The complaint was filed under case number 2:15-cv-06264 in the U.S. District Court for the Eastern District of Louisiana on November 23rd, 2015. The plaintiff filing is a New Jersey resident who claims that these manufacturers have failed to sufficiently warn current and potential patients about certain health risks which are potentially linked to the new-generation blood thinner.
Blood Thinning Drug Expected To Make Profit Despite Xarelto Lawsuit Filings
| Bloodthinnerhelp.com
By Joseph Osborne

BloodThinnerHelp.com reports on FiercePharma.com projected sales for Xarelto into 2018. According to analysts, the drug is projected to make an estimated $3.68 billion in sales despite the growing number of lawsuits against the manufacturers claiming that use of the drug resulted in adverse side effects.

Plaintiff Attorney Blog Posts

Xarelto Lawsuits & Settlements Guide
Mar 28, 2016 | ConsumerProtect.com
By Michael Bennett

A relatively new drug on the market, Xarelto has already been the subject of lawsuit claims that the drug caused harm to some users, and that the manufacturer failed to sufficiently warn users about the risks of taking this medication. Bayer is the manufacturer of Xarelto; a Johnson & Johnson subsidiary company, Janssen Pharmaceuticals, markets this drug in the U.S.
Xarelto Lawsuit Plaintiffs Claim Bayer, Johnson & Johnson Deceived Prominent Medical Journal
Mar 28, 2016 | Southern Med Law

A brief filed on behalf of thousands of plaintiffs who have Xarelto lawsuits pending in a federal multidistrict litigation has made some alarming claims regarding the conduct of Johnson & Johnson and Bayer. The brief, which was filed in the U.S. District Court, Eastern District of Louisiana, contends that the companies were aware that important lab data had been omitted from an analysis published last month in The New England Journal of Medicine (NEJM). According to The New York Times, plaintiffs assert that the drug makers were “complicit by staying silent, helping deceive the editors while the companies were in the midst of providing the very same data to regulators in the United States and Europe.”
Xarelto Injury Lawyers Serving Clients in the Denver, CO Area
Mar 31, 2016 | Xarelto Lawsuit

If you or someone you love took Xarelto or another blood-thinning drug and suffered serious or life-threatening consequences, you may be eligible to file a lawsuit. An experienced Xarelto lawsuit attorney in Denver can help with your case.

Full Text of Stories Below

Client Attorney Privileged/Attorney Work Product/At Request of Counsel

Plaintiff Attorney Press Releases

Patients File Class Action Xarelto Lawsuit in Canada

Mar 26, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on the Calgary Sun’s article concerning Canadian patients who have filed Xarelto lawsuits. The lead plaintiff in Canada’s class action suit alleges that she suffered uncontrollable bleeding after taking Xarelto in 2012. She claims that after doctors struggled to control the bleeding, she went into cardiac arrest.
The Canadian class action suit against the blood-thinning drug, manufactured by Johnson & Johnson and Bayer, came about a year after a multidistrict litigation panel was formed in the U.S. for similar cases. As of March 2015, Health Canada received about 1,100 reports of adverse side effects believed to be related to Xarelto. Multidistrict litigation No. 2592 in the U.S. has reached almost 3,000 cases and a smaller group of filings consolidated by the Philadelphia Court of Common Pleas into a mass tort program for cases filed in the Commonwealth of Pennsylvania has hit 620 cases.
Xarelto was first approved by the FDA in 2011 for preventing blood clots in deep vein thrombosis patients undergoing knee and hip replacements, atrial fibrillation, and for general use in reducing the recurrence of blood clots, and stent thrombosis in patients with acute coronary syndrome. A phase III study showed that 73 percent of study participants who took Xarelto suffered from an adverse side effect. Commonly reported side effects that have been attributed to the drug by those filing suits are pulmonary embolisms (blood clots in the lung), rectal bleeding, heart attack, stroke, epidural hematoma, internal bleeding, gastrointestinal bleeding and brain hemorrhages.
While thousands of cases against Xarelto manufacturers have already arisen, more are expected to be filed. The statute of limitations on those cases varies by state, usually ranging from two to three years from the time of injury.
As more cases are brought to court, Attorney Joseph Osborne is working to ensure that all those who believe they have been negatively affected by the blood-thinning drug have their questions answered and are able to explore their legal rights. Those individuals could be entitled to legal action and substantial financial compensation. Osborne is currently offering free legal consultations to qualifying individuals.
To request further Xarelto information, or to ask questions, please contact Joseph Osborne at (866) 425-8902.
http://www.digitaljournal.com/pr/2881976

Return to headline | Return to top
Portola Enters Agreement With Xarelto Manufacturer Bayer Amid Lawsuit Increases

Mar 26, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on Portola Pharmaceuticals’ announcement concerning a clinical collaboration with Bayer. Portola announced that it has decided to enter a collaboration with the manufacturers of Xarelto to include its Factor Xa inhibitor rivaroxaban in a clinical development program in Japan. Portola is developing an FDA designated breakthrough therapy called andexanet alfa to reverse anticoagulation in patients taking Factor Xa inhibitors such as Xarelto.
Terms of Portola’s agreement with Bayer include an upfront payment of $5 million and may include a milestone payment should Japanese MHLW (Ministry of Health Labour and Welfare) approve andexanet alfa as an antidote for Xarelto, according to statements from Portola. The group also entered into separate agreements with Bayer and Janssen Pharmaceuticals, Inc. to support studies of the antidote in the U.S. and Europe.
While this may be good news for future users of Xarelto, thousands of patients who have already used Xarelto have claimed to suffer adverse side effects including uncontrolled bleeding, which Portola’s new investigational drug is expected to stop.
An internal bleed can occur in many parts of the body. Internal bleeding occurs when damage to an artery or vein causes blood to leak out and pool in other areas of the body.
Other side effects plaintiffs claim to have suffered include heart attack, stroke, gastrointestinal bleeding and pulmonary embolisms. The alleged side effects are the crux of almost 3,000 lawsuits that have been filed federally in the U.S. Those cases have been consolidated into a multidistrict litigation panel in Eastern Louisiana. Those filed in the commonwealth of Pennsylvania have been consolidated by the Philadelphia Court of Common Pleas into a mass tort program which has reached 620 cases.
While those cases await trial, Attorney Joseph Osborne is working to ensure that those who believe they have been negatively affected by the blood-thinning drug are able to explore their legal rights. Qualifying individuals may be entitled to legal action and financial compensation. Osborne is currently offering free legal consultations to affected parties.
For more information about Xarelto, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2881994

Return to headline | Return to top
Xarelto Lawsuit Plaintiffs Note New York Times Article Discussing Potentially Defective Testing Device

Mar 28, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on the publication of a New York Times article which discussed an investigation by the U.S. Food and Drug Administration (FDA) into whether a recalled device used during Xarelto clinical testing could have affected the trial results leading up to the drug’s FDA approval in 2011.
In a recent New York Times article, it was noted that the FDA has started to ask Johnson & Johnson (Janssen), “…detailed questions about whether there was evidence that the device was malfunctioning while the trial was underway, according to a legal brief filed in federal court on Monday by lawyers for patients and their families who say they were injured by the drug. The lawyers also cited internal company documents that they said showed doctors were complaining to the trial leadership during the course of the study.”
The New York Times also reported that, “Regulators are looking at whether the malfunctioning device might have led doctors to give patients the wrong dose of warfarin, which could have led to additional bleeding episodes and given an unfair advantage to Xarelto.” It was indicated that Johnson & Johnson (Janssen) and Bayer reportedly, “…notified regulators that the device that was used in the trial had been recalled in 2014 because it was understating patients’ risk of bleeding.”
Since 2011, over just 5 year’s time, Xarelto has become the topic of more than 3,400 lawsuits. Over 2,800 of these complaints were filed in federal courts from across the nation and then transferred and consolidated to a single court in Eastern Louisiana by the U.S. Judicial Panel on Multidistrict Litigation, forming MDL number 2592. Additionally, over 600 Xarelto lawsuit complaints have been consolidated to form a mass tort program in Philadelphia, Pennsylvania by the Court of Common Pleas.
Of these thousands of filed lawsuits, plaintiffs all share similar allegations filed against Xarelto and its manufacturers, Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson corporation). Involved plaintiffs claim that Xarelto puts users at heightened risk for sudden and dangerous bleeding episodes. Some of the plaintiffs involved in current suits, in fact, have filed on behalf of their loved ones who have passed away due to fatal bleeding.
As plaintiffs involved in current Xarelto lawsuits await trial dates, Attorney Joseph Osborne is currently working to help other patients who have used Xarelto and have suffered from adverse events that they believe were caused by the drug. He wants to help ensure that affected patients will be given the critical opportunity to investigate their legal rights in the matter. These individuals may be entitled to substantial compensation through legal action. To better help those wishing to pursue justice, Attorney Osborne is offering complimentary Xarelto consultations for qualified parties at this time.
To obtain additional information, or to ask questions regarding Xarelto bleeding lawsuits, please contact Joseph Osborne, Esq. at (866) 425-8902.
http://www.keyc.com/story/31585123/xarelto-lawsuit-plaintiffs-note-new-york-times-article-discussing-potentially-defective-testing-device

Return to headline | Return to top
Xarelto Lawsuit Plaintiff Requests $4.35 Million In Lawsuit Claiming Dangerous Bleeding Episode

Mar 28, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on another lawsuit that has been filed against Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation), and multiple other defendants, regarding new-generation anticoagulant Xarelto. The plaintiff filing suit claims that the anticoagulant caused him to suffer from a sudden and uncontrollable bleeding episode.
The man’s complaint was transferred and consolidated with all federally-filed Xarelto lawsuits by the U.S. Judicial Panel on Multidistrict Litigation forming MDL No. 2592 in Eastern Louisiana. These lawsuits are being presided over by The Honorable Judge Eldon E. Fallon, who has currently ordered bellwether trial preparations and tentatively scheduled bellwether trial dates for early 2017.
Among the thousands of Xarelto lawsuits, this one is significant because it involves 90-counts and the plaintiff filing it is requesting $4.35 million in compensation. Court documents show that the plaintiff claims that Bayer and Janssen misleadingly marketed Xarelto as a safe and effective drug option for patients hoping to reduce their risk of strokes, and also that the defendants failed to adequately warn the public of potentially dangerous side effects that he now links to the drug.
Additionally, the plaintiff claims that these manufacturers were likely aware that the anticoagulant may cause a heightened risk of bleeding episodes for patients using it. Clinical studies conducted on the drug, the plaintiff notes, help to support this argument. He alleges that if the defendants were aware of these possible dangers, they acted with negligence by doing nothing to protect the public with this valuable information. The plaintiff stated, “Defendants use the results of the Rocket AF study, the Record studies, and the Einstein studies to promote Xarelto in their promotional materials, including the Xarelto website, which tout the positive results of those studies. However, defendants’ promotional materials fail to similarly highlight the increased risk of gastrointestinal bleeding and bleeding that required transfusion among other serious bleeding concerns.”
The U.S. Food and Drug Administration approved Xarelto in 2011 to treat patients with atrial fibrillation, pulmonary embolism, and deep vein thrombosis as well as those recovering from hip and knee replacement surgeries. As a new-generation blood thinner, it provided patients with freedoms that more traditional blood thinners had not been able to, and was therefore initially popular. Today, however, lawsuits surrounding the drug continue to increase in number. The Eastern Louisiana MDL is made up of over 2,800 complaints against the drug, while a group of more than 600 others was consolidated to form a mass tort program in Philadelphia, Pennsylvania by the Court of Common Pleas.
As lawsuit numbers are predicted by many to continue to rise, Attorney Joseph Osborne is working to assist patients who took Xarelto and who suffered from health problems that they attribute to the drug. He wants to ensure that these individuals will be provided with the opportunity to fully investigate their legal rights. Affected parties may be entitled to significant compensation attained through legal action. To assist those looking to pursue justice in the matter, Attorney Osborne is offering complimentary consultations for affected individuals.
To request further Xarelto lawsuit information, or to ask questions, please contact Attorney Osborne by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2882507

Return to headline | Return to top
Texas Plaintiffs File Xarelto Lawsuit Complaint Alleging Manufacturers Neglected To Warn Consumers Of Drugs Dangers

Mar 29, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on another lawsuit which has been filed against Xarelto manufacturers Bayer Healthcare and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson) in reference to the anticoagulant drug they produce, Xarelto. Xarelto is a new-generation blood-thinning drug which has been on the market for five year’s time. In those five years, it has become the topic of thousands of lawsuits from across the United States.
This particular lawsuit was filed by a Texas couple under case number 1:14-cv-04524. The complaint was filed in the Eastern District of New York prior to being transferred to join many other consolidated cases in Eastern Louisiana after a ruling by the U.S. Judicial Panel on Multidistrict Litigation. This consolidation created MDL number 2592.
The plaintiffs who have filed this lawsuit allege that defendants Bayer and Janssen neglected to adequately warn patients and medical professionals about dangerous possible risks connected to the use of their anticoagulant. The female plaintiff claims to have been prescribed Xarelto by her physician in order to prevent strokes which she was deemed at increased risk for due to her atrial fibrillation condition. She alleges that she used the anticoagulant for only 5 months when she suffered from a sudden and possibly life-threatening internal bleed. She also claims that this bleed left her with long-term medical needs that she still struggles with today.
After its initial launch, Xarelto was highly popular among consumers, offering freedoms that previous blood thinners hadn’t. Now, however, the drug is surrounded by more than 3,400 lawsuits which share concerning and common allegations. Involved plaintiffs allege that the anticoagulant can place patients taking it at increased risk for dangerous and sudden bleeding (both internal and external).
As these many plaintiffs await pending trial dates, and complaint filings continue to rise in number, Attorney Joseph Osborne is looking to assist patients who have taken Xarelto and who feel that they have suffered from adverse events due to their use of the blood thinner. He hopes to provide these individuals with the critical opportunity to fully investigate their legal rights. Affected individuals could be entitled to substantial compensation obtained through legal action. To better help those looking to pursue justice, Attorney Osborne is offering complimentary legal consultations to affected parties at this time.
To request additional information on Xarelto lawsuits, or to ask questions, please contact Attorney Joseph Osborne by calling (866) 425-8902.
http://www.fox5vegas.com/story/31585122/texas-plaintiffs-file-xarelto-lawsuit-complaint-alleging-manufacturers-neglected-to-warn-consumers-of-drugs-dangers#ixzz44J3iY1le

Return to headline | Return to top
Xarelto Lawsuit Plaintiff Requests $4.35 Million In Lawsuit Claiming Dangerous Bleeding Episode

Mar 29, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on another lawsuit that has been filed against Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation), and multiple other defendants, regarding new-generation anticoagulant Xarelto. The plaintiff filing suit claims that the anticoagulant caused him to suffer from a sudden and uncontrollable bleeding episode.
The man’s complaint was transferred and consolidated with all federally-filed Xarelto lawsuits by the U.S. Judicial Panel on Multidistrict Litigation forming MDL No. 2592 in Eastern Louisiana. These lawsuits are being presided over by The Honorable Judge Eldon E. Fallon, who has currently ordered bellwether trial preparations and tentatively scheduled bellwether trial dates for early 2017.
Among the thousands of Xarelto lawsuits, this one is significant because it involves 90-counts and the plaintiff filing it is requesting $4.35 million in compensation. Court documents show that the plaintiff claims that Bayer and Janssen misleadingly marketed Xarelto as a safe and effective drug option for patients hoping to reduce their risk of strokes, and also that the defendants failed to adequately warn the public of potentially dangerous side effects that he now links to the drug.
Additionally, the plaintiff claims that these manufacturers were likely aware that the anticoagulant may cause a heightened risk of bleeding episodes for patients using it. Clinical studies conducted on the drug, the plaintiff notes, help to support this argument. He alleges that if the defendants were aware of these possible dangers, they acted with negligence by doing nothing to protect the public with this valuable information. The plaintiff stated, “Defendants use the results of the Rocket AF study, the Record studies, and the Einstein studies to promote Xarelto in their promotional materials, including the Xarelto website, which tout the positive results of those studies. However, defendants’ promotional materials fail to similarly highlight the increased risk of gastrointestinal bleeding and bleeding that required transfusion among other serious bleeding concerns.”
The U.S. Food and Drug Administration approved Xarelto in 2011 to treat patients with atrial fibrillation, pulmonary embolism, and deep vein thrombosis as well as those recovering from hip and knee replacement surgeries. As a new-generation blood thinner, it provided patients with freedoms that more traditional blood thinners had not been able to, and was therefore initially popular. Today, however, lawsuits surrounding the drug continue to increase in number. The Eastern Louisiana MDL is made up of over 2,800 complaints against the drug, while a group of more than 600 others was consolidated to form a mass tort program in Philadelphia, Pennsylvania by the Court of Common Pleas.
As lawsuit numbers are predicted by many to continue to rise, Attorney Joseph Osborne is working to assist patients who took Xarelto and who suffered from health problems that they attribute to the drug. He wants to ensure that these individuals will be provided with the opportunity to fully investigate their legal rights. Affected parties may be entitled to significant compensation attained through legal action. To assist those looking to pursue justice in the matter, Attorney Osborne is offering complimentary consultations for affected individuals.
To request further Xarelto lawsuit information, or to ask questions, please contact Attorney Osborne by calling (866) 425-8902.
http://www.cbs19.tv/story/31580664/xarelto-lawsuit-plaintiff-requests-435-million-in-lawsuit-claiming-dangerous-bleeding-episode

Return to headline | Return to top
An Overview Of FDA Warnings Leading Into Building Xarelto Lawsuit Numbers

Mar 29, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on the warnings issued by the FDA for the blood-thinning drug Xarelto since its approval in 2011. According to the FDA, Xarelto, manufactured by Johnson & Johnson and Bayer AG, has undergone several required warnings and changes to labeling and advertisements for the drug since it was approved.
From January to March 2014 the manufacturers were required by the FDA to make changes to the language on the “black box warning” on the drug. The addition was allegedly needed to warn users about dangerous side effects including a lack of antidote and the risks associated with using the drug with epidural anesthesia and spinal puncture.
The companies had to make changes to their advertisements after the FDA claimed that the companies downplayed the possible side effects associated with the drug. From May to November of 2012 the FDA Cardiovascular and Renal Drugs Advisory committee convened to discuss the possibility of extending Xarelto’s uses, according to the FDA. Though the committee decided not to approve the drug because of concerns about bleeding, the FDA expanded the use indicating in a press release that three studies indicated that the drug was safe for treatment of deep vein thrombosis and pulmonary embolism. The announcement also noted bleeding as a possible “major side effect.”
The companies also received post market requirements from the FDA including providing a low-dose tablet, conducting a clinical study to determine risks affiliated with renal impairment and to track “risk factors, clinical management and outcomes of all major bleeding events and to report them through a quarterly report for three years.”
Since the drug hit the market in 2011, thousands of lawsuits have been filed federally against the manufacturers by plaintiffs claiming the drug caused adverse side effects such as gastrointestinal bleeding, rectal bleeding, internal bleeding, stroke, heart attack, pulmonary embolism, epidural hematoma and brain hemorrhages. Those cases have been consolidated into a multidistrict litigation panel in Eastern Louisiana that has now reached 2,800 cases. Those filed in state court in Pennsylvania have been combined into a mass tort program that has reached 620 cases. Bellwether trials on federally-filed cases are scheduled to begin in February 2017.
Until those cases are brought to court, Attorney Joseph Osborne is working to ensure that those individuals who have used the drug and have been negatively affected are able to explore their legal rights. Qualifying individuals may be entitled to financial compensation and legal action. Osborne is currently offering free legal consultations for affected parties.
For more information about Xarelto, or to ask questions, contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2883324

Return to headline | Return to top
Xarelto Lawsuit Numbers Continue To Increase As New Controversies Emerge Surrounding Drug

Mar 29, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on an article recently published on Health News Review by a guest blogger psychiatrist from the Washington, DC area. The article discusses what many different media outlets have been reporting recently: controversies surrounding critical clinical trials conducted on blood-thinning drug Xarelto, as well as data which may have been left out of a report to the New England Journal of Medicine.
The subject of these controversies is anticoagulant drug Xarelto, a new-generation blood thinner which was approved by the U.S. Food and Drug administration and released to market in 2011. This approval, however, as is now being discussed, may have been premature due to potentially incomplete clinical trial reports and a potentially faulty testing device during those clinical trials. The trials were meant to compare Xarelto to warfarin, a traditional blood thinner. When the BMJ reported that a malfunctioning blood test device was used during the trial, and that patients in the coumadin group may have been given higher doses of coumadin than what was considered optimal, patients from across the nation began to increasingly question Xarelto.
According to the Health News Review article author, “This isn’t the first time the NEJM has been embroiled in controversy over missing data. The Times referenced a past situation where NEJM editors knew of missing heart attack data from a clinical trial and allowed the study to be published anyway. The drug that was studied, the painkiller Vioxx (rofecoxib), was eventually withdrawn from the market, but not before leading to an estimated 55,000 deaths, as well as thousands of heart attacks and strokes.”
The author continues to discuss new medical reporting ethics which have been brought into question surrounding the drug. The author discusses transparency within data sharing and the importance of this honesty, stating, “As I pointed out in January, the NEJM editors have recently made a case against transparency and data sharing, in opposition to the push for universal acceptance of these principles by many in the research community. After publicly raising concerns that data-sharing would benefit so-called ‘research parasites’ who might have the temerity to use the data ‘to try to disprove what the original investigators had posited,’ Dr. Drazen quickly clarified that his stance against data-sharing didn’t apply to clinical trials such as the Xarelto study.”
These controversies only add to many allegations already surrounding the new-generation blood-thinning drug among patients from across the nation who have stepped forward to file lawsuits alleging that the drug can cause dangerous and even fatal bleeding side effects. Lawsuits now number over 3,400 across the United States, and have been consolidated to form two major groups. Federally-filed cases have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592 in Eastern Louisiana. They currently number over 2,800 complaints. In addition, more than 600 complaints have been consolidated by the Court of Common Pleas in Philadelphia, Pennsylvania to form a mass tort program.
As many plaintiffs await results of investigations surrounding these new controversies, and await trial dates as well, Attorney Joseph Osborne is working to ensure that anyone else who may have taken Xarelto and suffered from adverse health events that they attribute to their use of the drug will be afforded the important opportunity to fully explore their legal rights at this time. Affected patients may be eligible for significant compensation gained through legal action. To help those wishing to explore this avenue, Attorney Osborne is currently offering free legal consultations for affected parties.
To request additional information concerning Xarelto lawsuits, or to ask questions, please contact Attorney Osborne by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2883483

Return to headline | Return to top
Calgary Canada Class Action Xarelto Lawsuit Filed As Another Class Action Suit Is Likely Forming In Ontario

Mar 30, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on an article recently published in the Calgary Sun discussing the a class action lawsuit which was filed against Bayer Inc., one manufacturer of the new-generation, blood-thinning drug Xarelto in Calgary, Canada. According to the head plaintiff in this Canadian class action lawsuit, the drug caused her to suffer from an uncontrollable bleeding episode which allegedly almost led to cardiac arrest.
This Canadian class action lawsuit closely follows the formation of Multidistrict Litigation number 2592 in the United States, which involves a group of more than 2,800 lawsuits filed against Xarelto. This MDL was formed by the U.S. Judicial Panel on Multidistrict Litigation. In addition to this group of Xarelto lawsuits in the United States, another group of more than 600 cases has formed a mass tort program in Philadelphia, Pennsylvania, created by the Court of Common Pleas. These lawsuits were filed against Bayer as well as Johnson & Johnson subsidiary, Janssen Pharmaceuticals.
According to the Calgary Sun, it was reported that as of March 2015, Health Canada had received around 1,100 reports detailing adverse events experienced by patients using Xarelto. The article notes that, according to a Toronto lawyer, if the class action is successful, “…it would be in the millions of dollars.” The article notes that another class action suit may be forming in Ontario as well.
In the United States, Xarelto gained FDA approval in 2011 to treat patients with pulmonary embolism, deep vein thrombosis, and atrial fibrillation, as well as those recovering from hip and knee replacement surgeries. The drug was initially popular, launching onto the market as a revolutionary blood thinner that provided patients with more freedoms than traditional blood thinners had in the past. Since this time, however, Xarelto has become the subject of increasing controversies and is regarded by many as one of the most dangerous blood thinners on the market. The FDA has given the product two “black box” warnings, which are the most severe warnings a product can receive before being completely pulled from the market.
Commonly reported side effects that have been attributed to the drug by those filing suits are pulmonary embolisms (blood clots in the lung), rectal bleeding, heart attack, stroke, epidural hematoma, internal bleeding, gastrointestinal bleeding and brain hemorrhages.
As thousands of Xarelto lawsuit plaintiffs await trial, those involved expect that lawsuit numbers surrounding the anticoagulant drug will only continue to rise. As this continues, Attorney Joseph Osborne is working to help ensure that patients who believe they have suffered from adverse health events due to their use of Xarelto will be given the opportunity to fully evaluate their legal rights in the matter. These patients may be entitled to significant compensation attained through legal action. To better assist those affected, Attorney Osborne is offering complimentary legal consultations for qualified parties at this time.
To request additional information concerning Xarelto lawsuits, or to ask questions, please contact Attorney Joseph Osborne by calling (866) 425-8902.
http://www.keyc.com/story/31595222/calgary-canada-class-action-xarelto-lawsuit-filed-as-another-class-action-suit-is-likely-forming-in-ontario

Return to headline | Return to top
Xarelto Lawsuit Numbers Continue To Increase As New Controversies Emerge Surrounding Drug

Mar 30, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on an article recently published on Health News Review by a guest blogger psychiatrist from the Washington, DC area. The article discusses what many different media outlets have been reporting recently: controversies surrounding critical clinical trials conducted on blood-thinning drug Xarelto, as well as data which may have been left out of a report to the New England Journal of Medicine.
The subject of these controversies is anticoagulant drug Xarelto, a new-generation blood thinner which was approved by the U.S. Food and Drug administration and released to market in 2011. This approval, however, as is now being discussed, may have been premature due to potentially incomplete clinical trial reports and a potentially faulty testing device during those clinical trials. The trials were meant to compare Xarelto to warfarin, a traditional blood thinner. When the BMJ reported that a malfunctioning blood test device was used during the trial, and that patients in the coumadin group may have been given higher doses of coumadin than what was considered optimal, patients from across the nation began to increasingly question Xarelto.
According to the Health News Review article author, “This isn’t the first time the NEJM has been embroiled in controversy over missing data. The Times referenced a past situation where NEJM editors knew of missing heart attack data from a clinical trial and allowed the study to be published anyway. The drug that was studied, the painkiller Vioxx (rofecoxib), was eventually withdrawn from the market, but not before leading to an estimated 55,000 deaths, as well as thousands of heart attacks and strokes.”
The author continues to discuss new medical reporting ethics which have been brought into question surrounding the drug. The author discusses transparency within data sharing and the importance of this honesty, stating, “As I pointed out in January, the NEJM editors have recently made a case against transparency and data sharing, in opposition to the push for universal acceptance of these principles by many in the research community. After publicly raising concerns that data-sharing would benefit so-called ‘research parasites’ who might have the temerity to use the data ‘to try to disprove what the original investigators had posited,’ Dr. Drazen quickly clarified that his stance against data-sharing didn’t apply to clinical trials such as the Xarelto study.”
These controversies only add to many allegations already surrounding the new-generation blood-thinning drug among patients from across the nation who have stepped forward to file lawsuits alleging that the drug can cause dangerous and even fatal bleeding side effects. Lawsuits now number over 3,400 across the United States, and have been consolidated to form two major groups. Federally-filed cases have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592 in Eastern Louisiana. They currently number over 2,800 complaints. In addition, more than 600 complaints have been consolidated by the Court of Common Pleas in Philadelphia, Pennsylvania to form a mass tort program.
As many plaintiffs await results of investigations surrounding these new controversies, and await trial dates as well, Attorney Joseph Osborne is working to ensure that anyone else who may have taken Xarelto and suffered from adverse health events that they attribute to their use of the drug will be afforded the important opportunity to fully explore their legal rights at this time. Affected patients may be eligible for significant compensation gained through legal action. To help those wishing to explore this avenue, Attorney Osborne is currently offering free legal consultations for affected parties.
To request additional information concerning Xarelto lawsuits, or to ask questions, please contact Attorney Osborne by calling (866) 425-8902.
http://www.cbs19.tv/story/31590152/xarelto-lawsuit-numbers-continue-to-increase-as-new-controversies-emerge-surrounding-drug

Return to headline | Return to top
Woman Files Xarelto Lawsuit Alleging Life-Threatening Bleeding Incidents From Drug

Mar 30, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on a lawsuit that has been added to MDL No. 2592 in Eastern Louisiana in February. The plaintiff alleges that after taking Xarelto, manufactured by Bayer AG and Johnson & Johnson, from January 2014 to February 2014, she suffered serious bleeding incidents that she claims were a direct result of the drug. The suit contains 12 actions against the manufacturers including allegations that the companies failed to adequately warn patients about possible side effects and the fact that when the drug was released to the market there was no reversal agent. An antidote still has not been approved.
The drug was first introduced to the U.S. in 2011 and has been the subject of thousands of lawsuits since. Common injuries that plaintiffs pursuing legal action have alleged include gastrointestinal bleeding, brain hemorrhages, internal bleeding, rectal bleeding, pulmonary embolisms (blood clots in the lung), epidural hematoma, stroke, and heart attacks. Those cases filed federally have been consolidated in a multidistrict litigation panel in New Orleans, Louisiana and those filed in the commonwealth of Pennsylvania have been assigned to a mass tort program that has now reached 620 cases. This allows lawyers to focus on the organization of cases, and discovery in preparation for initial trials and settlement talks.
Bellwether trials for these cases have been scheduled for February 2017.
As plaintiffs await their day in court, Attorney Joseph Osborne is working to help ensure that anyone who has taken Xarelto and has also experienced negative side effects that they attribute to the drug will be given the opportunity to thoroughly investigate their legal rights. These people could be entitled to significant compensation. Osborne is offering complimentary legal consultations to affected parties at this time.
To request further information on Xarelto, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.fox5vegas.com/story/31595876/woman-files-xarelto-lawsuit-alleging-life-threatening-bleeding-incidents-from-drug#ixzz44OgeJCwF

Return to headline | Return to top
Xarelto Lawsuit Plaintiffs Take Note Of New Controversies Surrounding Anticoagulant Drug

Mar 29, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on new controversies surrounding blood-thinning drug Xarelto after,“...a document claimed that two major pharmaceutical companies may have misled a medical journal by leaving out some critical data on their drug,” according to a recent online article from Business Insider.
The drug amongst all of this controversy is anticoagulant Xarelto, produced by manufacturers Bayer and Johnson & Johnson subsidiary Janssen Pharmaceuticals. Xarelto was approved by the U.S. Food and Drug Administration in 2011 to treat patients recovering from hip and knee replacement surgeries, as well as those with deep vein thrombosis, pulmonary embolism, and atrial fibrillation. The new-generation blood thinner has been very popular since its launch to market, in fact, Business Insiderreports that, “In 2015, Xarelto made about $1.8 billion in U.S. sales. But it’s also the subject of more than 5,000 lawsuits, 500 of which involve patient deaths.”
Katie Thomas of The New York Times reportedly discovered a footnote within a federal legal briefing that indicated the possibility of evidence showing that Xarelto’s manufacturers (Johnson & Johnson and Bayer) potentially excluded critically important data which was requested by a peer reviewer at the prestigious New England Journal of Medicine. Business Insider notes that, “That data could have given the reviewer an idea of how the blood readings from one device compare to another.”
This newly discovered controversy follows months of public concern regarding a clinical trial test which took place to determine the effectiveness of Xarelto when compared to traditional blood thinner warfarin. It was discovered post-study that one of the blood-clot testing devices used during the trial had been recalled and may have falsely impacted the testing results.
It has been reported that at this time, both the U.S. Food and Drug Administration and the European Medicine Agency are investigating this faulty blood-testing device to determine whether it may have led to a premature approval for Xarelto.
Thousands of plaintiffs currently involved in Xarelto lawsuits from across the nation are anxiously awaiting the findings of these investigations. Those involved predict that Xarelto lawsuit numbers will only continue to grow in the meantime. As time goes on, Attorney Joseph Osborne is working to do his part to help ensure that anyone who used Xarelto and feels that they suffered from the drug will be given the opportunity to fully explore their legal rights. These patients may be entitled to legal action and significant compensation. To better help those wishing to learn more, Attorney Osborne is currently offering free legal consultations to affected parties.
To request additional information concerning Xarelto lawsuits, or to ask questions, please call Attorney Osborne at (866) 425-8902.
http://www.digitaljournal.com/pr/2884346

Return to headline | Return to top
Xarelto Lawsuit Claims Drug Caused Hemorrhagic Pericardial Effusion

Mar 30, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on an Arizona lawsuit that alleges the blood-thinning drug, Xarelto, caused a woman to suffer a life-threatening hemorrhagic pericardial effusion, a medical condition in which blood fills the sac around the heart and gets in the way of normal heart contractions. The woman who filed case number 2:16-cv-01359 claimed that she took Xarelto for less than two weeks and that she was diagnosed in 2014 with hemorrhagic pericardial effusion, pericardial tamponade and pleural effusion. In addition to claims that Xarelto was the reason for this diagnosis, the case further claims that Bayer AG and Johnson & Johnson withheld information about the lack of antidote, when the drug was released to the market, to reverse the drug's blood-thinning effects.
This case is the latest of several thousand suits claiming that her bleeding complications resulted from use of the drug. Since December 2014 Xarelto lawsuits have been consolidated in New Orleans, Louisiana as part of a multidistrict litigation panel before U.S. District Judge Eldon Fallon. Judge Fallon has issued a "bellwether"program for the cases, through which early trial dates for the suits are expected to be scheduled for May and February of 2017. Those suits filed in Pennsylvania state court have been consolidated into a mass tort program for more efficient management.
Xarelto was approved by the FDA in 2011 for preventing blood clots and deep vein thrombosis in patients undergoing knee and hip replacements, as well as for atrial fibrillation, reducing the recurrence of blood clots and stent thrombosis. A phase III study of the use of Xarelto showed that 73% of participants in the study suffered from adverse side effects including internal bleeding or anemia. Commonly reported injuries include heart attacks, stroke, internal bleeding gastrointestinal bleeding, brain hemorrhages,rectal bleeding, pulmonary embolisms (blood clots in the lung), epidural hematoma.
As litigation is expected to continue, Attorney Joseph Osborne is currently working with patients who have taken Xarelto and may have suffered serious health complications alleged to be associated with the drug. Those who have suffered from complications have the opportunity to evaluate their legal rights and may be entitled to substantial compensation. Osborne is currently offering free consultations for those affected.
To request more information on Xarelto bleeding lawsuits, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2885040

Return to headline | Return to top
NJ Resident Files Xarelto Lawsuit Claiming Drug Caused Nearly Fatal GI Bleeding Episode

Mar 30, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on another lawsuit which has been filed against Bayer AG and Janssen Pharmaceuticals in relation to the anticoagulant drug they manufacture, Xarelto. The complaint was filed under case number 2:15-cv-06264 in the U.S. District Court for the Eastern District of Louisiana on November 23rd, 2015. The plaintiff filing is a New Jersey resident who claims that these manufacturers have failed to sufficiently warn current and potential patients about certain health risks which are potentially linked to the new-generation blood thinner.
Unfortunately, this plaintiff is not alone in his complaints. Lawsuits filed against the same defendants in reference to Xarelto have appeared in high volume from across the United States. Cases filed in federal courts were transferred and consolidated to a single court by the U.S. JPML and now form multidistrict litigation number 2592. Today, they number over 2,800 complaints and are being overseen by Judge Eldon Fallon in Eastern Louisiana. Additionally, another mass tort program of over 600 lawsuits was formed in Philadelphia, Pennsylvania by the Court of Common Pleas. Plaintiffs in these cases also share strikingly similar complaints.
Further information found in lawsuit documents for this specific lawsuit indicated that after only six months of taking Xarelto, the plaintiff suddenly suffered from what he claims was a potentially life-threatening gastrointestinal bleed. Gastrointestinal bleeds can occur anywhere along the GI tract within the body, and can be fatal. Although the plaintiff is relieved to have survived the ordeal, he indicates that because of it, he will have long-term health problems and, therefore, extensive future medical bills.
Attorney Joseph Osborne understands the seriousness of these potential side effects, and how concerning these allegations might be for patients currently dependent upon Xarelto. He is working to assist anyone who believes their health was negatively affected after using Xarelto. He feels that it is critical that these individuals are offered the opportunity to fully investigate their legal rights in the matter. Affected parties may be entitled to substantial compensation gained through legal action. To better assist those who wish to look further into legal action, Attorney Osborne is offering free Xarelto consultations for qualifying patients at this time.
To ask questions regarding Xarelto lawsuits, or to request additional information, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.newschannel10.com/story/31599361/nj-resident-files-xarelto-lawsuit-claiming-drug-caused-nearly-fatal-gi-bleeding-episode

Return to headline | Return to top
Xarelto Plaintiffs From Texas File Lawsuit Claiming Drugs Manufacturers Failed To Warn Consumers Of Concerning Side Effects

Mar 31, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on concerning details from a lawsuit filed against Xarelto manufacturers Bayer AG and Johnson & Johnson subsidiary Janssen Pharmaceuticals. Xarelto is a new-generation blood-thinning drug which first appeared on the market in 2011, providing blood thinner patients with new freedoms that traditional blood thinners had been unable to.
This particular lawsuit was first filed in the Eastern District of New York under case number 1:14-cv-04524 by a couple from Texas. The couple claims that defendants Janssen and Bayer failed to properly inform consumers and patients about potentially dangerous risks linked to the use of Xarelto.
Detailing how they came to this conclusion, the plaintiffs explain that the wife was prescribed Xarelto by a family physician as a treatment for her atrial fibrillation heart condition, which can potentially put sufferers at increased risk for strokes. The woman claims that she used Xarelto for just 5 month’s time before she suddenly experienced a potentially life-threatening internal bleed. The bleed, she says, has left her with the need for long-term medical care, and, therefore, continued mounting medical bills.
Xarelto gained approval by the United States Food and Drug Administration in 2011. It was intended as a treatment for patients recovering from knee or hip replacement surgeries, who were deemed at increased risk for the development of blood clots or strokes. Although it gained FDA market approval, Xarelto was also the recipient of two “black box” warnings from the agency. These “black box” warnings are the most strict warnings the FDA is able to attach to a product before fully pulling it from the market.
Unfortunately, these Texas plaintiffs are not alone in their claims. Across the United States, thousands of plaintiffs have now filed lawsuits against Xarelto manufacturers alleging much the same. Many plaintiffs discuss a variety of bleeding episodes, some of which were fatal, and all of which, they claim, were caused by the anticoagulant.
Cases federally-filed against Xarelto have now been transferred and consolidated to a single court by the U.S. Judicial Panel on Multidistrict Litigation. These cases number over 2,800 today and are being overseen in the Eastern District of Louisiana by Judge Eldon Fallon. They were consolidated to form MDL number 2592. In addition, more than 600 other Xarelto-related lawsuits have been consolidated in Philadelphia, Pennsylvania by the Court of Common Pleas, forming a mass tort program.
As thousands of Xarelto plaintiffs await trial, Attorney Joseph Osborne is working to help other patients who feel that they have been negatively affected by using the drug. He wants to ensure that these individuals are provided the opportunity of fully investigating their legal rights in the matter. Affected individuals may be entitled to legal action and significant compensation. To help assist, Attorney Osborne is currently offering free legal consultations to qualified parties.
To request additional information on Xarelto lawsuits, or to ask questions, contact Attorney Joseph Osborne by calling (866) 425-8902.
http://www.fox14tv.com/story/31616189/xarelto-plaintiffs-from-texas-file-lawsuit-claiming-drugs-manufacturers-failed-to-warn-consumers-of-concerning-side-effects

Return to headline | Return to top
NJ Resident Files Xarelto Lawsuit Claiming Drug Caused Nearly Fatal GI Bleeding Episode

Apr 1, 2016 | Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on another lawsuit which has been filed against Bayer AG and Janssen Pharmaceuticals in relation to the anticoagulant drug they manufacture, Xarelto. The complaint was filed under case number 2:15-cv-06264 in the U.S. District Court for the Eastern District of Louisiana on November 23rd, 2015. The plaintiff filing is a New Jersey resident who claims that these manufacturers have failed to sufficiently warn current and potential patients about certain health risks which are potentially linked to the new-generation blood thinner.
Unfortunately, this plaintiff is not alone in his complaints. Lawsuits filed against the same defendants in reference to Xarelto have appeared in high volume from across the United States. Cases filed in federal courts were transferred and consolidated to a single court by the U.S. JPML and now form multidistrict litigation number 2592. Today, they number over 2,800 complaints and are being overseen by Judge Eldon Fallon in Eastern Louisiana. Additionally, another mass tort program of over 600 lawsuits was formed in Philadelphia, Pennsylvania by the Court of Common Pleas. Plaintiffs in these cases also share strikingly similar complaints.
Further information found in lawsuit documents for this specific lawsuit indicated that after only six months of taking Xarelto, the plaintiff suddenly suffered from what he claims was a potentially life-threatening gastrointestinal bleed. Gastrointestinal bleeds can occur anywhere along the GI tract within the body, and can be fatal. Although the plaintiff is relieved to have survived the ordeal, he indicates that because of it, he will have long-term health problems and, therefore, extensive future medical bills.
Attorney Joseph Osborne understands the seriousness of these potential side effects, and how concerning these allegations might be for patients currently dependent upon Xarelto. He is working to assist anyone who believes their health was negatively affected after using Xarelto. He feels that it is critical that these individuals are offered the opportunity to fully investigate their legal rights in the matter. Affected parties may be entitled to substantial compensation gained through legal action. To better assist those who wish to look further into legal action, Attorney Osborne is offering free Xarelto consultations for qualifying patients at this time.
To ask questions regarding Xarelto lawsuits, or to request additional information, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.newschannel10.com/story/31599361/nj-resident-files-xarelto-lawsuit-claiming-drug-caused-nearly-fatal-gi-bleeding-episode

Return to headline | Return to top
Blood Thinning Drug Expected To Make Profit Despite Xarelto Lawsuit Filings

| Bloodthinnerhelp.com

By Joseph Osborne

BloodThinnerHelp.com reports on FiercePharma.com projected sales for Xarelto into 2018. According to analysts, the drug is projected to make an estimated $3.68 billion in sales despite the growing number of lawsuits against the manufacturers claiming that use of the drug resulted in adverse side effects.
In 2011, the Food & Drug Administration approved Xarelto (rivaroxaban), manufactured by Johnson & Johnson and Bayer AG, for preventing blood clots and deep vein thrombosis in patients undergoing knee and hip replacements, atrial fibrillation, and for general use in reducing the recurrence of blood clots, and stent thrombosis in patients with acute coronary syndrome. In 2013, the manufacturers of Xarelto profited with sales of $1.4 billion and in January 2014, the first lawsuit alleging Xarelto was the cause of a patient’s death because of uncontrollable bleeding was filed. Since then, thousands more lawsuits have been filed, resulting in a mass tort program in Philadelphia that has now reached 620 cases as well as the creation of a Multidistrict Litigation panel in Eastern Louisiana that is currently up to 2,800 cases. Most lawsuits allege that Xarelto caused uncontrollable internal bleeding resulting in death or serious injury.
One of the most common side effects patients using Xarelto have reported is internal bleeding. Physicians usually check for internal bleeding by first completing a thorough history of the patient and may do blood tests or imaging tests to look for the bleeding source. The possibility of gastrointestinal bleeding may be checked by a fiber optic scope that looks into the esophagus and stomach. Other common reported injuries that patients have associated with Xarelto are brain hemorrhages, rectal bleeding, pulmonary embolisms (blood clots in the lung), epidural hematoma, stroke and heart attacks.
As plaintiffs await their day in court, Attorney Joseph Osborne is working to help ensure that everyone affected negatively by the drug will have the opportunity to explore their legal options. These individuals may be entitled to legal action and significant compensation. Currently, Osborne is offering free legal consultations for qualifying individuals.
For more information or to ask questions about Xarelto, contact Joseph Osborne Esq. by calling (866) 425-8902.
http://www.tristateupdate.com/story/31616407/blood-thinning-drug-expected-to-make-profit-despite-xarelto-lawsuit-filings

Return to headline | Return to top

Plaintiff Attorney Blog Posts

Xarelto Lawsuits & Settlements Guide

Mar 28, 2016 | ConsumerProtect.com

By Michael Bennett

A relatively new drug on the market, Xarelto has already been the subject of lawsuit claims that the drug caused harm to some users, and that the manufacturer failed to sufficiently warn users about the risks of taking this medication. Bayer is the manufacturer of Xarelto; a Johnson & Johnson subsidiary company, Janssen Pharmaceuticals, markets this drug in the U.S.
There have been thousands of Xarelto lawsuits filed so far, with the majority being handled as part of a Multidistrict Litigation (MDL) process. Settlements from litigation against a similar product, Pradaxa, resulted in payment of $650 million to over 3000 plaintiffs in the first set of cases, and a second litigation effort is in progress.
Xarelto
Approved for sale in the U.S. in 2011, Xarelto (Rivaroxaban) was aggressively marketed for use as a new anticoagulant. Millions of users have been prescribed this medicine to prevent blood clot formation that occurs with atrial fibrillation (irregular heartbeat) or following hip or knee replacement surgery. It also was given as a remedy to prevent new blood clots in patients suffering from deep vein thrombosis (DVT) or pulmonary embolus (PE).
Purpose – Xarelto (Rivaroxaban) is an anticoagulant that blocks certain clotting proteins in blood. The main reason for using this drug is to prevent blood clots from forming when there is atrial fibrillation (irregular heartbeat) in a patient. It also is prescribed to patients who have had knee or hip replacement surgery.
Conditions Treated: Xarelto is prescribed for conditions that involve blood clotting that needs prevention. These conditions include: clots in lungs or in a deep vein, clots that occur following knee or hip replacement surgery, clots that occur in chronic atrial fibrillation.
Prescription – This prescription drug is primarily used to prevent blood clots following surgery for hip or knee replacement, and in patients who experience a certain irregular heartbeat condition. It also is prescribed for patients who have blood clots due to deep vein thrombosis (DVT) or pulmonary embolus (PE).
Problems – There is no antidote for this drug. If it causes uncontrollable bleeding from thinning the blood, there is no remedy. This is the most dangerous potential side effect. Patients also are told there is no need to regularly monitor blood, as is required with other drugs like Warfarin. There also is a higher risk of bleeding if the patient takes Xarelto with certain other medications, including Aspirin, NSAIDs, drugs that contain heparin, Warfarin (Coumadin, Jantoven), Clopidogrel (Plavix), or other drugs prescribed to treat or prevent clot formation. In addition to interaction with other anti-coagulant and prescription medications, Xarelto may react with non-prescription medicines, vitamins or herbal supplements.
People who take Xarelto should thoroughly discuss this medicine, its usage, and potential risks with their doctor before taking it. Certain medical conditions can be negatively affected by this drug and there is a very long list of potential side effects that can occur due to taking Xarelto. In one study, 73 percent of people who took Xarelto did suffer from at least one adverse side effect.
Xarelto Timeline
Xarelto was first approved for sale and use in Canada, in 2008. By 2011, it was approved in the United States by the FDA. Since that time, over 13 million prescriptions have been written in the U.S., and according to theXarelto website, it is the “#1 Prescribed Blood Thinner” in its class.
2011 – First approvals by FDA for sale in US.
July 1 – Approved for use in DVT & PE, hip & knee replacement surgery
November 4 – Approved for blood clot prevention and strokes due to atrial fibrillation
2012 – First reports of doctor concerns about bleeding safety, June 14th
2013 – Adverse events reported.
Jan 1 – FED MedWatch says 593 complaints link Xarelto to bleeding by end of 2012
July 1 – Bayer, Johnson & Johnson report Xarelto sales of $827 million for first half of 2013
September – Germany – Der Spiegel reports 968 adverse events during first 8 months of 2013, including 72 deaths
October 17 – Added to most dangerous drugs list; 10th reported to FDA for side effects
November 21 – American Heart Association suggests Xarelto causes higher risk (3x) for internal bleeding in acutely ill patients and in those with acute coronary syndrome (ACS) (4x).
2014 – Lawsuits, higher sales, recall issued, higher risks reported, and doctors get kickbacks for promoting drug.
January 16 – FDA votes against approval for use of Xarelto for ACS.
April 15 – First lawsuit filed for bleeding death of family member using Xarelto
June 14 – Bayer faces 10 lawsuits for internal bleeding injury or death caused by Xarelto
October 14 – Xarelto sales total over $1 billion for 2014
October 15 – FDA and J&J recall 13,500 bottles of Xarelto – concerns about microbial contamination
October 16 – Link between Xarelto and liver damage is found by Swiss researchers
December 9 – Increased risk for intestinal bleeding is higher with Xarelto than with Warfarin confirmed by U of Tel Aviv researchers
December 12 – Xarelto bleeding lawsuits are assigned in consolidation order from JPML to U.S. District Judge Eldon E. Fallon, Eastern District Federal Court, Louisiana
2015 – Kickbacks, second mass tort court created for new victims, more lawsuits, court date is scheduled for first Xarelto cases.
January 7 – Report that in last 5 months of 2013, doctors were paid almost $20 million to promote blood thinners like Xarelto
January 21 – Second mass tort court is created by Philadelphia judge for new group of lawsuits filed by victims suffering internal bleeding allegedly caused by Xarelto
August 17 – Total of 1,231 Xarelto bleeding lawsuits have now been filed in federal MDL court.
September 17 – First Xarelto cases are scheduled by Xarelto MDL Judge Eldon Fallon to begin February 6, 2017.
2016 – More lawsuits pending in Xarelto MDL court.
January 15 – 2,826 internal bleeding lawsuits reported as now filed and pending
2017 – Hearing in Xarelto MDL court is scheduled for February 6th.
Xarelto Side Effects
Side effects are a concern for people using Xarelto, an anticoagulant medicine. The most common and dangerous side effect of Xarelto is considered to be uncontrollable bleeding complications. This medication is a strong blood thinner, designed to prevent blood clots that result from a variety of medical conditions. Some side effects may not require medical attention, or they may go away as the body gets used to Xarelto. There may be an increased risk for bleeding when Xarelto is used by certain patient groups, including those with uncontrolled and severe arterial hypertension or those using other treatments that affect hemostasis.
Common Systemic Side Effects
Use of Xarelto can result in a variety of problems with the internal systems of the body. The following are the most common systemic side effects that users of this drug have experienced.
Hematologic – Bleeding is the most common effect
Gastrointestinal – The entire digestive system, including constipation, diarrhea, vomiting, bleeding, pain, and hemorrhages
Nervous system – dizziness, headache, cerebral hemorrhage, intracranial bleeding
Cardiovascular – deep vein thrombosis, hypertension, tachycardia, stroke (during transition from Rivaroxaban (active ingredient in Xarelto) to Warfarin in some patients
Hepatic – increased transaminases, liver problems
Renal – impairment, potential for renal failure,
Hypersensitivity – anaphylactic shock or reaction, hypersensitivity
Dermatologic – blister, hemorrhages, contusion, rash, wound secretion, itching, cutaneous and subcutaneous bleeding
Genitourinary – urinary retention, hemorrhage in urogenital tract or vagina
Metabolic – hyperglycemia, increased LDH, amylase and lipase
Musculoskeletal – arthralgia, back pain, muscle cramping or spasm, osteoarthritis, extremity pain
Ocular – hemorrhage in the eye, conjunctival hemorrhage
Psychiatric – Anxiety, sleep disorders
Respiratory – sinusitis, shortness of breath, oropharyngeal pain, nosebleed, hemotypsis
Other – Fatigue, decreased energy and general strength
Many common side effects have been reported by users of Xarelto. One website, Drugs.com, reports that over 50 different problems, ranked common to rare, are potential side effects that can occur when using Xarelto (generic name: Rivaroxaban).
Typical side effects related to use of Xarelto include
:Bleeding – in gums, bloody stools, coughing up blood, increase in menstrual flow or vaginal bleeding, nosebleeds, prolonged bleeding from cuts, vomiting of bloody material
Pain – back pain, headache, dizziness, leg weakness, difficulty breathing or swallowing, paralysis
Bowel or Bladder dysfunction – red or black stools, red or dark brown urine
Skin disorders – numbness, burning, itching, tingling feelings
Side effects that are less common or rare are many, and the list includes: fainting, wound secretion, arm/leg pain, and burning or difficult urination. More rare problems involve the systemic problems mentioned above. Symptoms include: blurred vision, chills, blisters, fast or irregular heartbeat, hives, loss of appetite, puffiness in the facial area and eyes, yellow eyes or skin, and muscle spasms.
Xarelto Lawsuit & Settlement
People who have used Xarelto and experienced side effects, disability or lost a loved one to death from using this drug can file a lawsuit to obtain compensation for their financial losses and emotional injuries. In some cases, this is the only way to make the drug companies accountable for allowing the manufacture and sale of dangerous drugs that cause harm to users.
Plaintiffs who have already filed Xarelto lawsuits are accusing the makers of this drug with negligence and failure to warn users of potential dangers. In addition to this issue, it has been disclosed that doctors were paid $20 million to promote the use of dangerous blood thinning drugs like Xarelto. The primary defendants in the initial group of Xarelto lawsuits are Bayer and Janssen Pharmaceuticals.
Lawsuit claims presented in the Xarelto case are similar to claims made in other personal injury lawsuits. Reasons for filing a Xarelto lawsuit include recovery of fair compensation for financial hardships caused by medical treatment, long-term care and lost wages. The injured parties may also seek compensation for non-economic claims like pain and suffering, and for their mental and emotional stress. Compensation to relatives who care for loved ones suffering from side effects or damage due to use of this drug include non-economic damage claims for their emotional distress, as well as economic damage claims to recover expenses they paid out for care of their loved one. When there is a death from use of Xarelto, survivors seek compensation for funeral and burial expenses.
Xarelto Lawyer/Attorney
If you have been harmed by taking Xarelto or you helped a loved one who was harmed by or died from taking Xarelto, it is important to seek legal assistance from a legal professional who has handled many Xarelto cases. An experienced Xarelto Lawyer/Attorney will have current knowledge of the status of existing lawsuits against the makers of this drug. They also will understand the tort system that allowed a judge to put the first group of lawsuits into a multi-district litigation status.
Multi-District Litigation (MDL) is a method for handling multiple claims against a defendant, bringing lawsuits from across the country into one courtroom. New claims may be added to this group, put into a new group or handled separately, depending on the circumstances of the legal issues. Your attorney knows how to manage your case to bring about the best possible results for you. You can start with a free consultation, so there is no reason to not consult right away with an experienced Xarelto Lawyer/Attorney. Since there may also be a statute of limitations that could affect your eligibility to file claims, contact your chosen attorney immediately.
Negligence is a key point to prove in these types of lawsuits. It has already been established that the manufacturers of Xarelto were negligent by not informing users of the bleeding dangers and other side effects that occur due to use of this drug. Adding to the dangers of use is the fact that Xarelto does not have an antidote, so bleeding can become uncontrolled and even fatal in some cases. If you or a loved one has been harmed or died due to use of Xarelto, you deserve fair compensation. Bring your concerns to our experienced Xarelto Lawyer/Attorney for resolution of your claims and the best possible outcome. Call us today!
http://www.consumerprotect.com/xarelto-lawsuits-settlements-guide/

Return to headline | Return to top
Xarelto Lawsuit Plaintiffs Claim Bayer, Johnson & Johnson Deceived Prominent Medical Journal

Mar 28, 2016 | Southern Med Law

A brief filed on behalf of thousands of plaintiffs who have Xarelto lawsuits pending in a federal multidistrict litigation has made some alarming claims regarding the conduct of Johnson & Johnson and Bayer. The brief, which was filed in the U.S. District Court, Eastern District of Louisiana, contends that the companies were aware that important lab data had been omitted from an analysis published last month in The New England Journal of Medicine (NEJM). According to The New York Times, plaintiffs assert that the drug makers were “complicit by staying silent, helping deceive the editors while the companies were in the midst of providing the very same data to regulators in the United States and Europe.”

“The report published by the Times is disturbing, and raises serious questions about the data used to obtain regulatory approval for Xarelto,” says Dr. François Blaudeau, the founder of Southern Med Law. As both an attorney and a practicing physician, Dr. Blaudeau possesses unique insight into the various legal and medical issues at the center of the growing Xarelto litigation.
Xarelto was approved by the U.S. Food & Drug Administration (FDA) in 2011, largely based on the Rocket-AF study. According to the times, that trial compared the number of strokes and bleeding events experienced by patients taking Xarelto with those using warfarin. However, last year it was discovered that a testing device used to make sure warfarin patients enrolled in the study received the correct dose of the drug had been recalled in 2014. If the device malfunctioned during Rocket-AF, the results would have suggested that Xarelto was superior to warfarin.
Rocket-AF was overseen by the Duke Clinical Research Institute, which last month published a re-analysis of the study in the NEJM. They concluded that the faulty testing device didn’t impact the trial’s results. But according to the Times, it now appears that some lab data might have been withheld which should have been published in the follow-up analysis. The data in question compared test results of the recalled device’s readings at a central laboratory, taking blood samples at the 12 and 24 month mark of the trial.
The editor at the NEJM acknowledged that they were unaware of the omitted data until a reporter from the Times asked them about it. However, “they dismissed its relevance and said they stood by the article’s analysis,” the report said.
More than 3,000 Xarelto lawsuits are now pending in the Eastern District of Louisiana, all of which were filed on behalf of patients who suffered dangerous internal bleeding and other problems allegedly associated with the blood thinning medication. Among other things, plaintiffs charge that the manufacturers of the drug wrongly marketed it as an improvement over warfarin. (In Re: Xarelto Litigation, Case ID 150102349)
Southern Med Law continues to review product liability claims on behalf of patients who may have been harmed by Xarelto. If you or a loved one experienced life-threatening internal bleeding or other complications while using this medication, please contact the Firm as soon as possible to learn more about your legal rights. You can arrange for a free, no obligation Xarelto lawsuit review by calling Southern Med Law today, at 205-547-5525.
About Southern Med Law and Filing A Xarelto Bleeding Lawsuit: Throughout his career, Dr. Blaudeau has worked hard to develop a strong reputation in healthcare litigation. His first-hand knowledge of medicine has made the Southern Med Law team an aggressive and effective attorney and advocate for those who were harmed due to negligent pharmaceutical companies. If you or a loved one where harmed by Xarelto, please contact Southern Med Law today to learn more about your legal rights. Call today for a free, no obligation Xarelto lawsuit review by filling out our online form, or by calling the office directly at 205-547-5525.
https://www.southernmedlaw.com/xarelto-lawsuit-plaintiffs-claim-bayer-johnson-johnson-deceived-prominent-medical-journal/2792

Return to headline | Return to top
Xarelto Injury Lawyers Serving Clients in the Denver, CO Area

Mar 31, 2016 | Xarelto Lawsuit

If you or someone you love took Xarelto or another blood-thinning drug and suffered serious or life-threatening consequences, you may be eligible to file a lawsuit. An experienced Xarelto lawsuit attorney in Denver can help with your case.
Who is liable when a dangerous drug like Xarelto results in preventable injuries to patients? According to an article in Business Insider, more than 5,000 lawsuits currently are pending against Johnson & Johnson and Bayer, the developers of the drug. And of those claims, around 500 involve a patient’s death. For patients and family members of those fatally injured by this medication, their lawsuits allege that the drugmakers may have known that there were serious questions surrounding the safety of Xarelto. At Zaner Harden Law, we are committed to assisting Denver residents who have sustained injuries from dangerous drugs and the companies that manufacture them.
What is Xarelto?
Xarelto, which goes by the generic name rivaroxaban, is a medication used most frequently to prevent blood clots, according to a fact sheet from WebMD. It is often prescribed for patients who suffer from atrial fibrillation, as well as to patients following hip or knee replacement surgeries after which blood clots can be more likely to form. Xarelto is also used in certain situations to treat blood clots, from deep vein thrombosis (DVT) to pulmonary embolus (PE). It is a medication that can be prescribed either to treat blood clots or as a preventive drug to help patients avoid blood clots in the first place.
How does it work? The WebMD fact sheet explains that Xarelto is an anticoagulant medication that “works by blocking certain clotting proteins in your blood.”Harmful Side Effects of Xarelto
As WebMD explains, Xarelto can result in less severe side effects, including easy bruising and minor bleeding (for instance, a temporary nose bleed). However, there are also more serious side effects from Xarelto, primarily including serious bleeding. The WebMD fact sheet cites the following as signs and symptoms of serious bleeding that can have debilitating and fatal consequences:Any unusual pain, swelling, or general discomfort;Unusual bruising;Long-lasting bleeding from a minor cut or from your gums;Frequent and/or persistent nosebleeds;Unusually heavy or unusually prolonged menstrual period;Pink or dark-colored urine;Bloody, black, or tarry stools;Coughing blood;Vomiting that looks dark or bloody;Severe headaches;Dizziness and/or fainting;Unusual or persistent tiredness and/or weakness; andDifficulty swallowing.
Filing a Xarelto Lawsuit
Drugmakers have a duty to alert consumers to the serious risks of using a medication. In a safety communication, the U.S. Food and Drug Administration (FDA) explained the serious and sometimes fatal risks of uncontrollable bleeding when using Xarelto. For many patients, this drug is not safe for use. If you lost a loved one as a result of injuries caused by this harmful prescription medication, you may be able to file a Xarelto lawsuit and should discuss your case with an experienced advocate.
Contact a Denver Xarelto Injury Lawyer
When drug manufacturers do not properly warn patients about the uncontrolled bleeding risks of a medication, they should be held liable for injuries that happen. If you or someone you love took Xarelto and suffered serious complications, a dedicated Denver Xarelto injury lawyer can discuss your options with you today. Contact Zaner Harden Law to learn more about our services.

Return to headline | Return to top

Full Text of Stories Below

Add recipients

Suggested